Log in
NASDAQ:MNOV

MediciNova News Headlines

$5.50
+0.06 (+1.10 %)
(As of 10/26/2020 12:00 AM ET)
Add
Compare
Today's Range
$5.33
Now: $5.50
$5.53
50-Day Range
$4.67
MA: $5.39
$5.99
52-Week Range
$2.79
Now: $5.50
$13.25
Volume125,920 shs
Average Volume708,436 shs
Market Capitalization$244.05 million
P/E RatioN/A
Dividend YieldN/A
Beta1.49

Headlines

MediciNova (NASDAQ MNOV) News Headlines Today

Source:
DateHeadline
MediciNova (NASDAQ:MNOV) Is In A Strong Position To Grow Its Business - Yahoo FinanceMediciNova (NASDAQ:MNOV) Is In A Strong Position To Grow Its Business - Yahoo Finance
finance.yahoo.com - October 26 at 1:39 PM
MediciNova (NASDAQ:MNOV) Is In A Strong Position To Grow Its BusinessMediciNova (NASDAQ:MNOV) Is In A Strong Position To Grow Its Business
finance.yahoo.com - October 26 at 1:39 PM
MediciNova, in Collaboration with the University of Sydney and the Australasian Gastro-Intestinal Trials Group, Announces Plans for a Multi-center, Phase 2b Study to Evaluate MN-166 (ibudilast) in Chemotherapy-Induced Peripheral Neuropathy - GlobeNewswireMediciNova, in Collaboration with the University of Sydney and the Australasian Gastro-Intestinal Trials Group, Announces Plans for a Multi-center, Phase 2b Study to Evaluate MN-166 (ibudilast) in Chemotherapy-Induced Peripheral Neuropathy - GlobeNewswire
globenewswire.com - October 22 at 8:05 PM
MediciNova on go with ibudilast mid-stage study in chemo-induced nerve damageMediciNova on go with ibudilast mid-stage study in chemo-induced nerve damage
seekingalpha.com - October 22 at 10:03 AM
MediciNova, in Collaboration with the University of Sydney and the Australasian Gastro-Intestinal Trials Group, Announces Plans for a Multi-center, Phase 2b Study to Evaluate MN-166 (ibudilast) in Chemotherapy-Induced Peripheral NeuropathyMediciNova, in Collaboration with the University of Sydney and the Australasian Gastro-Intestinal Trials Group, Announces Plans for a Multi-center, Phase 2b Study to Evaluate MN-166 (ibudilast) in Chemotherapy-Induced Peripheral Neuropathy
finance.yahoo.com - October 22 at 10:03 AM
MediciNova Appoints Carolyn Beaver to its Board of Directors and as Audit Committee ChairMediciNova Appoints Carolyn Beaver to its Board of Directors and as Audit Committee Chair
finance.yahoo.com - October 21 at 7:48 AM
MediciNova Announces Positive Findings on MN-001 (tipelukast) in Acute Liver Injury Model to be Presented at The Liver Meeting Digital Experience™ 2020MediciNova Announces Positive Findings on MN-001 (tipelukast) in Acute Liver Injury Model to be Presented at The Liver Meeting Digital Experience™ 2020
finance.yahoo.com - October 13 at 4:49 PM
Medicinova (MNOV) Announces Positive Findings on MN-001 in Acute Liver Injury Model to be Presented at The Liver Meeting - StreetInsider.comMedicinova (MNOV) Announces Positive Findings on MN-001 in Acute Liver Injury Model to be Presented at The Liver Meeting - StreetInsider.com
streetinsider.com - October 13 at 7:22 AM
MediciNova Announces Positive Findings on MN-001 (tipelukast) in Acute Liver Injury Model to be Presented at The Liver Meeting Digital Experience™ 2020 - GlobeNewswireMediciNova Announces Positive Findings on MN-001 (tipelukast) in Acute Liver Injury Model to be Presented at The Liver Meeting Digital Experience™ 2020 - GlobeNewswire
globenewswire.com - October 13 at 7:22 AM
 Analysts Expect MediciNova, Inc. (NASDAQ:MNOV) Will Post Earnings of -$0.10 Per Share Analysts Expect MediciNova, Inc. (NASDAQ:MNOV) Will Post Earnings of -$0.10 Per Share
americanbankingnews.com - October 2 at 3:16 PM
Hologic Gets FDA Authorization for Asymptomatic Covid Test - TheStreetHologic Gets FDA Authorization for Asymptomatic Covid Test - TheStreet
thestreet.com - September 28 at 1:20 PM
MediciNova slumps 23% on ibudilast data in chemo-induced nerve damage - Seeking AlphaMediciNova slumps 23% on ibudilast data in chemo-induced nerve damage - Seeking Alpha
seekingalpha.com - September 24 at 6:26 PM
Company News for Sep 24, 2020Company News for Sep 24, 2020
finance.yahoo.com - September 24 at 1:26 PM
MediciNova Announces Positive Clinical Results Regarding MN-166 (ibudilast) for Prevention of Chemotherapy-induced Peripheral Neuropathy Published in Cancer Chemotherapy and Pharmacology - GlobeNewswireMediciNova Announces Positive Clinical Results Regarding MN-166 (ibudilast) for Prevention of Chemotherapy-induced Peripheral Neuropathy Published in Cancer Chemotherapy and Pharmacology - GlobeNewswire
globenewswire.com - September 24 at 8:26 AM
MediciNova Announces Positive Clinical Results Regarding MN-166 (ibudilast) for Prevention of Chemotherapy-induced Peripheral Neuropathy Published in Cancer Chemotherapy and PharmacologyMediciNova Announces Positive Clinical Results Regarding MN-166 (ibudilast) for Prevention of Chemotherapy-induced Peripheral Neuropathy Published in Cancer Chemotherapy and Pharmacology
finance.yahoo.com - September 24 at 8:26 AM
MediciNova Stock Spikes on Coronavirus-Vaccine Progress - TheStreetMediciNova Stock Spikes on Coronavirus-Vaccine Progress - TheStreet
thestreet.com - September 24 at 3:26 AM
4 Sectors Moving Higher In Wednesdays Pre-Market Session - Benzinga4 Sectors Moving Higher In Wednesday's Pre-Market Session - Benzinga
benzinga.com - September 23 at 12:14 PM
American Well, MediciNova among major healthcare gainers, AC Immune, Wave Life Sciences leads losers pack - Seeking AlphaAmerican Well, MediciNova among major healthcare gainers, AC Immune, Wave Life Sciences leads losers' pack - Seeking Alpha
seekingalpha.com - September 23 at 12:14 PM
Stock Alert: MediciNova Gains 11% On Positive Covid-19 Vaccine Data - NasdaqStock Alert: MediciNova Gains 11% On Positive Covid-19 Vaccine Data - Nasdaq
nasdaq.com - September 23 at 12:14 PM
Thinking about buying stock in Axovant Gene Therapies, MediciNova, Canada Goose Holdings, Rite Aid Corp, or Wave Life Sciences? - PRNewswireThinking about buying stock in Axovant Gene Therapies, MediciNova, Canada Goose Holdings, Rite Aid Corp, or Wave Life Sciences? - PRNewswire
prnewswire.com - September 23 at 12:14 PM
The Daily Biotech Pulse: Coronavirus Vaccine Updates From J&J & MediciNova, Australian Regulatory Nod For GW Pharma - BenzingaThe Daily Biotech Pulse: Coronavirus Vaccine Updates From J&J & MediciNova, Australian Regulatory Nod For GW Pharma - Benzinga
benzinga.com - September 23 at 12:14 PM
The Daily Biotech Pulse: Coronavirus Vaccine Updates From J&J & MediciNova, Australian Regulatory Nod For GW PharmaThe Daily Biotech Pulse: Coronavirus Vaccine Updates From J&J & MediciNova, Australian Regulatory Nod For GW Pharma
finance.yahoo.com - September 23 at 12:14 PM
MediciNova Stock Spikes on Coronavirus-Vaccine ProgressMediciNova Stock Spikes on Coronavirus-Vaccine Progress
finance.yahoo.com - September 23 at 12:14 PM
MediciNova Announces that its Intranasal COVID-19 Vaccine Successfully Induced Systemic IgG and Mucosal IgA Neutralizing Antibodies Against SARS-CoV-2 in Mice using BC-PIV Vector Technology - GlobeNewswireMediciNova Announces that its Intranasal COVID-19 Vaccine Successfully Induced Systemic IgG and Mucosal IgA Neutralizing Antibodies Against SARS-CoV-2 in Mice using BC-PIV Vector Technology - GlobeNewswire
globenewswire.com - September 23 at 7:13 AM
MediciNova Announces that its Intranasal COVID-19 Vaccine Successfully Induced Systemic IgG and Mucosal IgA Neutralizing Antibodies Against SARS-CoV-2 in Mice using BC-PIV Vector TechnologyMediciNova Announces that its Intranasal COVID-19 Vaccine Successfully Induced Systemic IgG and Mucosal IgA Neutralizing Antibodies Against SARS-CoV-2 in Mice using BC-PIV Vector Technology
finance.yahoo.com - September 23 at 7:13 AM
MediciNova rallies on preclinical data supporting rationale of COVID-19 vaccineMediciNova rallies on preclinical data supporting rationale of COVID-19 vaccine
seekingalpha.com - September 13 at 4:21 AM
BUZZ-U.S. STOCKS ON THE MOVE-MediciNova Inc, Atara Biotherapeutics, Muscle Maker Inc - NasdaqBUZZ-U.S. STOCKS ON THE MOVE-MediciNova Inc, Atara Biotherapeutics, Muscle Maker Inc - Nasdaq
nasdaq.com - September 11 at 12:14 PM
Medicinova (MNOV) Announces BioComos Intranasal RS Virus Vaccine Successfully Induced Neutralizing Antibodies against RS Virus in Mice using BC-PIV Technology - StreetInsider.comMedicinova (MNOV) Announces BioComo's Intranasal RS Virus Vaccine Successfully Induced Neutralizing Antibodies against RS Virus in Mice using BC-PIV Technology - StreetInsider.com
streetinsider.com - September 11 at 7:14 AM
MediciNova Announces that BioComos Intranasal RS Virus Vaccine Successfully Induced Neutralizing Antibodies against the RS Virus in Mice using BC-PIV Technology - GlobeNewswireMediciNova Announces that BioComo's Intranasal RS Virus Vaccine Successfully Induced Neutralizing Antibodies against the RS Virus in Mice using BC-PIV Technology - GlobeNewswire
globenewswire.com - September 11 at 7:14 AM
MediciNova Announces that BioComo’s Intranasal RS Virus Vaccine Successfully Induced Neutralizing Antibodies against the RS Virus in Mice using BC-PIV TechnologyMediciNova Announces that BioComo’s Intranasal RS Virus Vaccine Successfully Induced Neutralizing Antibodies against the RS Virus in Mice using BC-PIV Technology
finance.yahoo.com - September 11 at 7:14 AM
MNOV: Update on Intranasal SARS-CoV-2 Vaccine… - Yahoo FinanceMNOV: Update on Intranasal SARS-CoV-2 Vaccine… - Yahoo Finance
finance.yahoo.com - September 2 at 6:50 PM
MNOV: Update on Intranasal SARS-CoV-2 Vaccine…MNOV: Update on Intranasal SARS-CoV-2 Vaccine…
finance.yahoo.com - September 2 at 6:50 PM
Pre-Open Stock Movers 9/01: (KODK) (ZM) (GOGO) (PRTH) (ATNX) (TTOO) (GNW) (More..) - StreetInsider.comPre-Open Stock Movers 9/01: (KODK) (ZM) (GOGO) (PRTH) (ATNX) (TTOO) (GNW) (More..) - StreetInsider.com
streetinsider.com - September 1 at 1:25 PM
BUZZ-U.S. STOCKS ON THE MOVE-Bloomin Brands, MediciNova, Build-A-Bear Workshop, Rackspace Technology - NasdaqBUZZ-U.S. STOCKS ON THE MOVE-Bloomin' Brands, MediciNova, Build-A-Bear Workshop, Rackspace Technology - Nasdaq
nasdaq.com - September 1 at 1:25 PM
MediciNova Announces Development Progress on Intranasal Formulation of SARS-CoV-2 Vaccine for COVID-19 - GlobeNewswireMediciNova Announces Development Progress on Intranasal Formulation of SARS-CoV-2 Vaccine for COVID-19 - GlobeNewswire
globenewswire.com - September 1 at 8:24 AM
MediciNova Announces Development Progress on Intranasal Formulation of SARS-CoV-2 Vaccine for COVID-19MediciNova Announces Development Progress on Intranasal Formulation of SARS-CoV-2 Vaccine for COVID-19
finance.yahoo.com - September 1 at 8:24 AM
MediciNova Announces Plans to Initiate a Clinical Trial of MN-166 (ibudilast) for COVID-19 Acute Respiratory Distress SyndromeMediciNova Announces Plans to Initiate a Clinical Trial of MN-166 (ibudilast) for COVID-19 Acute Respiratory Distress Syndrome
bloomberg.com - August 25 at 7:36 PM
MediciNova rallies on positive ibudilast data in alcohol use disorderMediciNova rallies on positive ibudilast data in alcohol use disorder
seekingalpha.com - August 9 at 12:39 AM
MediciNova Announces the Presentation of Positive Results from Phase 2 Trial of MN‑166 (ibudilast) in Alcohol Use Disorder at the American Psychological Association 2020 Annual Convention - GlobeNewswireMediciNova Announces the Presentation of Positive Results from Phase 2 Trial of MN‑166 (ibudilast) in Alcohol Use Disorder at the American Psychological Association 2020 Annual Convention - GlobeNewswire
globenewswire.com - August 6 at 10:39 AM
Thinking about buying stock in Biocept Inc, MediciNova Inc, Plug Power, IZEA Worldwide, or Teva Pharmaceutical? - PRNewswireThinking about buying stock in Biocept Inc, MediciNova Inc, Plug Power, IZEA Worldwide, or Teva Pharmaceutical? - PRNewswire
prnewswire.com - August 6 at 10:39 AM
MediciNova Announces the Presentation of Positive Results from Phase 2 Trial of MN‑166 (ibudilast) in Alcohol Use Disorder at the American Psychological Association 2020 Annual ConventionMediciNova Announces the Presentation of Positive Results from Phase 2 Trial of MN‑166 (ibudilast) in Alcohol Use Disorder at the American Psychological Association 2020 Annual Convention
finance.yahoo.com - August 6 at 10:39 AM
MNOV: Developing SARS-CoV-2 Vaccine Based on Parainfluenza Virus Vector… - Yahoo FinanceMNOV: Developing SARS-CoV-2 Vaccine Based on Parainfluenza Virus Vector… - Yahoo Finance
finance.yahoo.com - August 4 at 12:18 PM
MNOV: Developing SARS-CoV-2 Vaccine Based on Parainfluenza Virus Vector…MNOV: Developing SARS-CoV-2 Vaccine Based on Parainfluenza Virus Vector…
finance.yahoo.com - August 4 at 12:18 PM
MediciNova to Participate in the Morgan Stanley Virtual 18th Annual Global Healthcare Conference - GlobeNewswireMediciNova to Participate in the Morgan Stanley Virtual 18th Annual Global Healthcare Conference - GlobeNewswire
globenewswire.com - August 4 at 7:15 AM
MediciNova, Inc. 10-Q Jul. 28, 2020 5:06 PM - Seeking AlphaMediciNova, Inc. 10-Q Jul. 28, 2020 5:06 PM - Seeking Alpha
seekingalpha.com - July 29 at 8:46 AM
Mid-Day Market Update: Crude Oil Down Over 1%; Eastman Kodak Shares Jump - BenzingaMid-Day Market Update: Crude Oil Down Over 1%; Eastman Kodak Shares Jump - Benzinga
www.benzinga.com - July 29 at 3:46 AM
MediciNova Announces SARS-CoV-2 Vaccine Joint Development with BioComo and Mie University Japan - Yahoo FinanceMediciNova Announces SARS-CoV-2 Vaccine Joint Development with BioComo and Mie University Japan - Yahoo Finance
finance.yahoo.com - July 28 at 10:46 PM
Mid-Morning Market Update: Markets Open Lower; McDonalds Profit Misses Views - BenzingaMid-Morning Market Update: Markets Open Lower; McDonald's Profit Misses Views - Benzinga
www.benzinga.com - July 28 at 12:45 PM
MediciNova Is the Newest COVID-19 Stock - 24/7 Wall St.MediciNova Is the Newest COVID-19 Stock - 24/7 Wall St.
247wallst.com - July 28 at 12:45 PM
The Daily Biotech Pulse: Spectrum's Positive Dementia Readout, Pfizer, BioNTech Start Late-Stage Coronavirus Trial, resTORbio Receives COVID-19 FundingThe Daily Biotech Pulse: Spectrum's Positive Dementia Readout, Pfizer, BioNTech Start Late-Stage Coronavirus Trial, resTORbio Receives COVID-19 Funding
finance.yahoo.com - July 28 at 12:45 PM
This page was last updated on 10/27/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.